Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9)low-density lipoprotein cholesterol (LDL-C)low-density lipoprotein receptor (LDLR)cardiovascular disease (CVD)hypercholesterolemiaalirocmabevolocumabStatins are currently the major therapeutic strategies to lower low-density lipoprotein cholesterol (...
A new class of drugs can drastically lower your LDL cholesterol. Learn about how they work, who can take them, and what risks are involved.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) discovery has added a new paradigm to our understanding of cholesterol homeostasis and lipid metabolism. Since its discovery, PCSK9 inhibitors have become a widely investigated therapeutic class for lipid management in cardiovascular diseases and hyperc...
LDL-cholesterol reduction with PCSK9 inhibitors: A meta-analysis of randomised controlled trialsEvidence suggests that oxidative stress is a unifying feature underlying the toxic actions of particulate matter (PM). We have investigated whether individual plasma antioxidant concentrations (uric acid and ...
PCSK9 inhibitors and cardiovascular risk reduction 降脂新药如前蛋白转化酶枯草溶菌素 9(preprotein converting enzyme subtilisin kexin 9,PCSK9)抑制剂的应用,可使 LDL-C 水平降低 50%~70%,在他汀类药物治疗的基础上进一步减少主要不良心血管事件(major adverse cardiovascular event, MACE),再度证实了更大幅度降低...
PCSK9 inhibitors are a promising alternative for the many patients who are intolerant to statins. “It’s important to have another tool to get patients to target cholesterol levels when statins cannot be used,” Fazio said. ...
[8].Khan SU, et al. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ. 2022 May 4;377:e069116. [9].Jukema JW, et...
Diabetes mellitus NODM: New-onset diabetes mellitus pre-DM: Prediabetes PCSK9i: PCSK9 inhibitors LDL-C: LDL cholesterol FG: Fasting glucose A1c: Glycated haemoglobin References Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 caus...
目的 系统评价前蛋白转化酶枯草杆菌蛋白酶/溶菌素 9(proprotein convertase subtilisin/kexin type 9,PCSK9)抑制剂治疗高胆固醇血症的有效性与安全性。方法 计算机检索 The Cochrane Library、PubMed、EMbase、CNKI、WanFang Data 和 CBM 数据库,搜集 PCSK9 抑制剂治疗高胆固醇血症的随机对照试验(randomized controlled ...
[4] Koskinas K C, et al. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)[J]. J Am Coll Cardiol, 2019, 74(20): 2452-2462. [5] Gaba P, et al. Associ...